Restoring mortality data in the FOURIER trial of evolocumab in patients with CVD: a reanalysis based on regulatory data

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data – BMJ Open

Commentaries: 

Yet Another Story on Re-Analyzing a Major Trial – Sensible Medicine

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees – TCTMD

Experts Issue Caution for Evolocumab Following New Review of FOURIER Data; Amgen Disputes the Claims – AJMC